Renal Vein Thrombosis
Renal vein thrombosis (RVT) is the formation of a blood clot in the vein that drains blood from a kidney. It can affect one or both renal veins and may develop suddenly (acute) or gradually (chronic). Most cases in adults are associated with an underlying condition that promotes clotting—most commonly nephrotic syndrome (a condition with heavy protein loss in the urine), advanced cancer (particularly kidney cancer with tumor extension into the vein), certain autoimmune conditions, hypercoagulable states, trauma, or extrinsic compression. In infants, renal vein thrombosis has different causes and typically presents differently. Symptoms can range from severe flank pain and blood in the urine to no symptoms at all. Evaluation typically involves contrast-enhanced imaging (CT or MRI), laboratory testing, and evaluation for the underlying cause.
What is it?
The renal veins carry blood from the kidneys back to the heart through the inferior vena cava (the large vein in the abdomen). Each kidney has a renal vein: the left renal vein is typically longer and passes between the aorta and the superior mesenteric artery before joining the inferior vena cava; the right renal vein is shorter and joins the inferior vena cava directly. Renal vein thrombosis (RVT) is the formation of a blood clot within one or both renal veins. When the vein becomes blocked, blood cannot easily drain from the kidney, which can lead to swelling of the kidney, reduced kidney function, and, in some cases, hemorrhage or other complications.
RVT can be classified based on timing and extent.
Acute RVT develops suddenly and typically causes prominent symptoms. It is often associated with a triggering event such as an acute change in a predisposing condition. Chronic RVT develops gradually and often causes fewer symptoms; it may be identified incidentally on imaging done for other reasons. Unilateral RVT affects one kidney and often causes symptoms limited to that side; the other kidney can typically compensate. Bilateral RVT (which is less common) can significantly reduce overall kidney function and is more serious.
Extension of the clot into the inferior vena cava is an important finding that affects treatment planning and complications. Clots can also break off from the renal vein or vena cava and travel to the lungs (pulmonary embolism), a significant complication of RVT.
Several conditions predispose to renal vein thrombosis in adults.
Nephrotic syndrome is one of the most important causes. It is a condition in which the kidneys leak large amounts of protein into the urine, resulting in swelling, low blood protein, and, importantly for RVT, a hypercoagulable state (increased tendency to clot). Membranous nephropathy is the type of nephrotic syndrome most strongly associated with RVT, though other types can also predispose. The risk is highest with more severe protein loss and low blood albumin levels.
Kidney cancer (particularly renal cell carcinoma) can extend directly into the renal vein, forming a tumor thrombus that may be confused with (or coexist with) a blood clot. Tumor thrombus can extend into the inferior vena cava and, in advanced cases, up into the right side of the heart. Distinguishing tumor thrombus from bland (blood clot) thrombus is important for planning treatment.
Certain autoimmune conditions—particularly systemic lupus erythematosus (lupus), especially when associated with antiphospholipid antibody syndrome—predispose to thrombosis, including RVT.
Hypercoagulable conditions of various types, both inherited (such as factor V Leiden mutation, prothrombin gene mutation, protein C or S deficiency, and antithrombin deficiency) and acquired (such as pregnancy, oral contraceptives, cancer, and antiphospholipid antibody syndrome), predispose to thrombosis, including RVT.
Trauma to the kidney or its blood vessels can cause RVT, either directly from vessel injury or from associated changes.
Extrinsic compression of the renal vein—by tumors, lymph nodes, retroperitoneal fibrosis, or other structures—can predispose to thrombosis.
Prior kidney transplantation can be complicated by RVT, particularly in the early postoperative period.
Severe dehydration and certain medical conditions can predispose to RVT.
In infants, particularly premature and severely ill newborns, RVT has different causes and often occurs in the context of severe illness (such as sepsis, dehydration, or complications of prematurity). In infants, RVT often presents with a palpable abdominal mass, blood in the urine, and low platelets.
Symptoms of RVT depend on whether it is acute or chronic, unilateral or bilateral, and the specific underlying cause. Acute unilateral RVT often causes sudden flank or back pain that can be severe, blood in the urine, and, in some cases, worsening kidney function. Acute bilateral RVT can cause more severe symptoms including significant reduction in urine output and acute kidney injury, and is a more urgent situation. Chronic RVT may cause few or no symptoms and be identified incidentally on imaging. RVT associated with nephrotic syndrome may present with worsening of protein loss in the urine or acute worsening of kidney function.
Symptoms of complications may also be present. Pulmonary embolism (clot traveling to the lungs) can cause shortness of breath, chest pain, coughing (sometimes with blood), and, in severe cases, sudden death. Renal infarction (from clot extending into arterial branches or from associated arterial changes) can occur in some cases.
Diagnosis is based on imaging. Contrast-enhanced CT with venous-phase imaging is one of the primary tests and clearly shows the clot as a filling defect within the renal vein. It also identifies associated findings such as kidney swelling, evidence of underlying causes (such as tumors), and extension into the inferior vena cava. MRI, including MR venography, provides similar information without ionizing radiation and is particularly useful in specific situations (such as young patients, pregnant patients, or patients with contrast contraindications). Doppler ultrasound can identify some cases of RVT and is useful in specific settings (such as in pregnancy, in infants, or when radiation should be avoided), though it has limitations for evaluating deeper structures. Catheter venography is now rarely needed for diagnosis but may be used in specific circumstances.
Laboratory testing typically includes complete blood count, kidney function (creatinine and estimated glomerular filtration rate), coagulation studies, and, when appropriate, evaluation for hypercoagulable conditions (such as testing for factor V Leiden, prothrombin gene mutation, protein C and S levels, antithrombin levels, antiphospholipid antibodies, and others). Urinalysis often shows blood and, in nephrotic syndrome, significant protein. Additional testing depends on the clinical context.
Evaluation for underlying causes is essential and depends on the clinical setting. This may include kidney biopsy (particularly when nephrotic syndrome is suspected but the specific cause is not known), imaging for cancer or lymphadenopathy, evaluation for autoimmune conditions, and evaluation for other predisposing conditions.
Important to Know
Management of renal vein thrombosis depends on whether it is acute or chronic, the extent of thrombosis, the underlying cause, symptoms, kidney function, and patient factors. Care is typically coordinated by nephrologists, hematologists, and, when needed, interventional radiologists or interventional vascular specialists, oncologists (when cancer is involved), and other specialists.
For most adults with RVT, anticoagulation is the mainstay of treatment. Initial anticoagulation with heparin or low-molecular-weight heparin is typically started as soon as the diagnosis is made and, in many cases, when it is strongly suspected while awaiting confirmation. Long-term anticoagulation is then continued, typically for at least several months and often longer depending on the underlying cause and risk factors for recurrence.
The choice of long-term anticoagulant depends on several factors. Warfarin has traditionally been used and remains appropriate in many settings, particularly for patients with antiphospholipid antibody syndrome (in whom direct oral anticoagulants have been associated with less favorable outcomes in some studies). Direct oral anticoagulants (DOACs, such as apixaban, rivaroxaban, dabigatran, and edoxaban) are increasingly used for many types of venous thromboembolism and are often chosen for their convenience and safety profile, though careful consideration of the specific indication is important. For patients with cancer-associated thrombosis, DOACs and low-molecular-weight heparin are both accepted options, with the choice depending on cancer type and other factors.
Duration of anticoagulation is individualized. For RVT associated with a reversible risk factor (such as a resolved acute illness), a defined course of anticoagulation may be sufficient. For RVT associated with an ongoing predisposing condition (such as persistent nephrotic syndrome, active cancer, or a strong hereditary hypercoagulable state), long-term or indefinite anticoagulation may be appropriate. Decisions balance the risk of recurrent thrombosis against the risk of bleeding.
For patients with severe acute RVT—particularly those with bilateral thrombosis, significant kidney dysfunction, or extension into the inferior vena cava with concerning features—more aggressive interventions may be considered in selected cases. Catheter-directed thrombolysis (delivery of clot-dissolving medication directly to the clot through a catheter) or mechanical thrombectomy (physical removal of the clot) may improve outcomes in specific patients, though the evidence base is limited and the decision is individualized. These interventions are typically performed by interventional radiologists or interventional vascular specialists.
For patients with tumor thrombus from kidney cancer extending into the renal vein or inferior vena cava, treatment is directed by principles of kidney cancer management and typically involves surgical removal of the kidney and the tumor thrombus in appropriate patients. This is often a major surgery that may require cardiac or vascular surgical involvement when thrombus extends into the vena cava at higher levels or into the heart. Systemic therapy may also be part of treatment for advanced kidney cancer.
Treatment of underlying conditions is essential to prevent recurrence.
For nephrotic syndrome, treatment is directed at the specific underlying kidney disease (such as membranous nephropathy). Treatment may include corticosteroids, other immunosuppressive medications, and specific therapies for the diagnosed condition. Prevention of thromboembolism is an important consideration in patients with severe nephrotic syndrome, and preventive anticoagulation is considered in patients at particularly high risk (such as those with membranous nephropathy and very low albumin levels).
For autoimmune conditions, treatment of the underlying autoimmune process is essential, often with immunosuppressive medications and, in patients with antiphospholipid antibody syndrome, long-term anticoagulation.
For inherited hypercoagulable conditions, family evaluation may be appropriate. Genetic counseling is important, and management of pregnancy and other high-risk situations follows established protocols.
For patients with RVT related to trauma, extrinsic compression, or other identifiable and reversible causes, treatment of the underlying cause is important.
For patients with kidney transplant complicated by RVT, urgent evaluation is essential because RVT can lead to graft loss. Care is coordinated with the transplant team.
Care of kidney function is important throughout. For patients with acute RVT causing acute kidney injury, supportive care may be needed. For patients with chronic RVT and reduced kidney function, standard chronic kidney disease management principles apply.
For infants with RVT, care is coordinated by pediatric specialists and includes treatment of underlying illness, supportive care, and, in some cases, anticoagulation. Long-term follow-up is important because affected kidneys may have reduced function or, in severe cases, become atrophic.
Care during pregnancy in patients with a history of RVT or with active RVT during pregnancy requires special attention. Warfarin has implications for the fetus and is typically avoided during pregnancy, particularly in the first trimester and near delivery, with low-molecular-weight heparin often preferred. Coordination with obstetrics, maternal-fetal medicine, and hematology is essential.
Long-term follow-up includes monitoring for complications, monitoring of the underlying condition, and management of anticoagulation. For patients on long-term anticoagulation, regular follow-up is important to monitor for bleeding, medication interactions, and other complications.
Care is typically coordinated by nephrologists, hematologists, and, when needed, other specialists. Imaging and laboratory findings are interpreted alongside the patient’s symptoms, examination, past medical history, and broader clinical context rather than in isolation.
Patient education plays an important role. Understanding the diagnosis, the underlying cause when identified, the rationale for the treatment plan (particularly the importance of anticoagulation adherence), warning signs of complications (including pulmonary embolism and bleeding), and, when relevant, family screening for hereditary conditions all contribute to better outcomes.
Red flag symptoms include severe flank or back pain, significant decrease or absence of urine output (particularly if both kidneys may be affected or in a solitary kidney), sudden shortness of breath, chest pain (which may indicate pulmonary embolism), coughing up blood, sudden severe headache with neurological symptoms, sudden weakness or numbness, sudden difficulty speaking or vision changes (which may suggest stroke), significant bleeding while on anticoagulation (severe headache, black or bloody stools, coughing up blood, severe bruising), severe abdominal pain, or rapid clinical deterioration. These warrant immediate emergency evaluation, as they may indicate pulmonary embolism, stroke, major bleeding, or other serious complications.